相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Amyloid-β Cleaner for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction
Ruiyuan Liu et al.
ADVANCED SCIENCE (2020)
Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy
Yanjie Liu et al.
NANO LETTERS (2020)
Can mouse models mimic sporadic Alzheimer's disease?
Bettina M. Foidl et al.
NEURAL REGENERATION RESEARCH (2020)
Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
Chiara Bastiancich et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma
Vivek Bhaskaran et al.
NATURE COMMUNICATIONS (2019)
A walk through tau therapeutic strategies
Santosh Jadhav et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Marie Albert et al.
BRAIN (2019)
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy
Meng Zheng et al.
ADVANCED MATERIALS (2019)
Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo
Kristen L. Kozielski et al.
BIOMATERIALS (2019)
A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma
Sang-Soo Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis
Michael X. Henderson et al.
NATURE NEUROSCIENCE (2019)
Systematic Evaluation of Light-Activatable Biohybrids for Anti-Glioma Photodynamic Therapy
Collin T. Inglut et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Biodegradable Mesoporous Silica Achieved via Carbon Nanodots-Incorporated Framework Swelling for Debris-Mediated Photothermal Synergistic Immunotherapy
Min Qian et al.
NANO LETTERS (2019)
Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Anna Galstyan et al.
NATURE COMMUNICATIONS (2019)
Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases
Asahi Tomitaka et al.
DRUG DISCOVERY TODAY (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy
Gulsah Erel-Akbaba et al.
ACS NANO (2019)
Hybrid clusterbombs' as multifunctional nanoplatforms potentiate brain tumor immunotherapy
Qi Shen et al.
MATERIALS HORIZONS (2019)
Advancing Cancer Immunotherapies with Nanotechnology
Jenny Lou et al.
ADVANCED THERAPEUTICS (2019)
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Maria-Carmela Speranza et al.
NEURO-ONCOLOGY (2018)
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Jann N. Sarkaria et al.
NEURO-ONCOLOGY (2018)
iRGD Modified Chemo-immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma
Jing Kuang et al.
ADVANCED FUNCTIONAL MATERIALS (2018)
Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment
Chenmeng Qiao et al.
ADVANCED MATERIALS (2018)
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Karolina Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
Near-infrared photoimmunotherapy targeting EGFRShedding new light on glioblastoma treatment
Thomas A. Burley et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment
Yuan Peng et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care
Stephanie Behrens et al.
INTERNATIONAL PSYCHOGERIATRICS (2018)
Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease
Donghoon Kim et al.
NATURE NANOTECHNOLOGY (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Stephen J. Bagley et al.
NEURO-ONCOLOGY (2018)
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Immobilization of Photo-Immunoconjugates on Nanoparticles Leads to Enhanced Light-Activated Biological Effects
Huang-Chiao Huang et al.
SMALL (2018)
Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy
Meng Zheng et al.
TRENDS IN BIOTECHNOLOGY (2018)
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
Barbara Oldrini et al.
NATURE COMMUNICATIONS (2018)
Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody
Tadanobu Nagaya et al.
Oncotarget (2018)
Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy
Elif Ozdemir-Kaynak et al.
FRONTIERS IN PHYSIOLOGY (2018)
Recent advances in applying nanotechnologies for cancer immunotherapy
Reza Mahjub et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Immunomodulating Nanomedicine for Cancer Therapy
Zhigang Liu et al.
NANO LETTERS (2018)
Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons
Jordi Pujols et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Combination Glioma Therapy Mediated by a Dual-Targeted Delivery System Constructed Using OMCN-PEG-Pep22/DOX
Wenbo Qian et al.
SMALL (2018)
Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine
Yan Zou et al.
ADVANCED MATERIALS (2018)
Promising vaccines for treating glioblastoma
Adam M. Swartz et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes
Yanan Shi et al.
JOURNAL OF CONTROLLED RELEASE (2018)
New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease
Guoxin Zhang et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Benchmarking in vitro tissue-engineered blood-brain barrier models
Jackson G. DeStefano et al.
FLUIDS AND BARRIERS OF THE CNS (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Debarati Ghosh et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Current trends in mouse models of glioblastoma
Masafumi Miyai et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials
Eunice L. Lozada-Delgado et al.
LIFE SCIENCES (2017)
Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma
Shanshan Wang et al.
MOLECULAR THERAPY (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brain Pericytes As Mediators of Neuroinflammation
Justin Rustenhoven et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Biomarkers for Parkinson's Disease: Recent Advancement
Sharvari Lotankar et al.
NEUROSCIENCE BULLETIN (2017)
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity
Mikako Ogawa et al.
ONCOTARGET (2017)
Near-infrared photoimmunotherapy: a comparison of light dosing schedules
Fusa Ogata et al.
ONCOTARGET (2017)
Correlation of Circulating T Lymphocytes and Intracranial Hypertension in Intracerebral Hemorrhage
Wanqiang Su et al.
WORLD NEUROSURGERY (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Tools for translation: non-viral materials for therapeutic mRNA delivery
Khalid A. Hajj et al.
NATURE REVIEWS MATERIALS (2017)
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
Matthias Van Woensel et al.
SCIENTIFIC REPORTS (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma
Hongyu Liu et al.
CANCER LETTERS (2017)
Engineering challenges for brain tumor immunotherapy
Johnathan G. Lyon et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
M. Beatriz S. Lopes
ACTA NEUROPATHOLOGICA (2017)
Current approaches to the treatment of Parkinson's Disease
J. Michael Ellis et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Russell Maxwell et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Augmented glioma-targeted theranostics using multifunctional polymer-coated carbon nanodots
Shanshan Wang et al.
BIOMATERIALS (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault et al.
CLINICAL CANCER RESEARCH (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Timing and Type of Immune Checkpoint Therapy Affect the Early Radiographic Response of Melanoma Brain Metastases to Stereotactic Radiosurgery
Jack M. Qian et al.
CANCER (2016)
Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis
Chiara Bardella et al.
CANCER CELL (2016)
Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery
Benjami Oller-Salvia et al.
CHEMICAL SOCIETY REVIEWS (2016)
Cellular immunotherapy for malignant gliomas
Yi Lin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Recent advances and future of immunotherapy for glioblastoma
Neha Kamran et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Harnessing nanomedicine for therapeutic intervention in glioblastoma
Anna Gutkin et al.
EXPERT OPINION ON DRUG DELIVERY (2016)
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
Laura Garros-Regulez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme
Szu-Ting Chou et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Therapeutic approaches in Parkinson's disease andrelated disorders
Elvira Valera et al.
JOURNAL OF NEUROCHEMISTRY (2016)
How can rAAV--synuclein and the fibril -synuclein models advance our understanding of Parkinson's disease?
Laura A. Volpicelli-Daley et al.
JOURNAL OF NEUROCHEMISTRY (2016)
From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery
William A. Banks
NATURE REVIEWS DRUG DISCOVERY (2016)
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
Emese Szabo et al.
NEURO-ONCOLOGY (2016)
Review: Parkinson's disease: from synaptic loss to connectome dysfunction
Arianna Bellucci et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2016)
Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies
Hua Jing et al.
THERANOSTICS (2016)
Strategies for transporting nanoparticles across the blood-brain barrier
Tian-Tian Zhang et al.
BIOMATERIALS SCIENCE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
Penetrating the Blood-Brain Barrier: Promise of Novel Nanoplatforms and Delivery Vehicles
Iqbal Unnisa Ali et al.
ACS NANO (2015)
Down syndrome and Alzheimer's disease: Common pathways, common goals
Dean Hartley et al.
ALZHEIMERS & DEMENTIA (2015)
Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis
Celeste M. Karch et al.
BIOLOGICAL PSYCHIATRY (2015)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Synthetic Nanoparticles for Vaccines and Immunotherapy
Darrell J. Irvine et al.
CHEMICAL REVIEWS (2015)
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma
Giovanna Lollo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model
Diana L. Castillo-Carranza et al.
JOURNAL OF NEUROSCIENCE (2015)
Convection-enhanced delivery to the central nervous system
Russell R. Lonser et al.
JOURNAL OF NEUROSURGERY (2015)
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay et al.
LANCET NEUROLOGY (2015)
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Feng Liu et al.
MOLECULAR CELL (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2015)
Blood-brain barrier modeling: challenges and perspectives
Tobias Ruck et al.
NEURAL REGENERATION RESEARCH (2015)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
Immunotherapeutic Approaches for Alzheimer's Disease
Thomas Wisniewski et al.
NEURON (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug
Martyn A. Sharpe et al.
EBIOMEDICINE (2015)
Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?
Avijit Banik et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
Ariadna Recasens et al.
ANNALS OF NEUROLOGY (2014)
Antibodies and protein misfolding: From structural research tools to therapeutic strategies
Erwin De Genst et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Galectin-1 and Immune Suppression during Radiotherapy
James W. Welsh et al.
CLINICAL CANCER RESEARCH (2014)
Immunotherapy for Brain Cancer: Recent Progress and Future Promise
Christopher M. Jackson et al.
CLINICAL CANCER RESEARCH (2014)
Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review
Allal Boutajangout et al.
GERONTOLOGY (2014)
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
Samir Mitragotri et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases
He-Jin Lee et al.
NATURE REVIEWS NEUROLOGY (2014)
Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease
Kaj Blennow et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Parkinson's disease: animal models and dopaminergic cell vulnerability
Javier Blesa et al.
FRONTIERS IN NEUROANATOMY (2014)
Active immunotherapy options for Alzheimer's disease
Bengt Winblad et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Alzheimer's Disease: Pathophysiology and Applications of Magnetic Nanoparticles as MRI Theranostic Agents
Houshang Amiri et al.
ACS CHEMICAL NEUROSCIENCE (2013)
Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier
Silke Krol et al.
CHEMICAL REVIEWS (2013)
Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment
Jason R. Cannon et al.
EXPERIMENTAL NEUROLOGY (2013)
The future of CpG immunotherapy in cancer
Behnam Badie et al.
IMMUNOTHERAPY (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Altered galectin-1 serum levels in patients diagnosed with high-grade glioma
Tina Verschuere et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss
Robert M. Cohen et al.
JOURNAL OF NEUROSCIENCE (2013)
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Manfred Westphal et al.
LANCET ONCOLOGY (2013)
Physiology of Blood-Brain Interfaces in Relation to Brain Disposition of Small Compounds and Macromolecules
N. Strazielle et al.
MOLECULAR PHARMACEUTICS (2013)
The many faces of alpha-synuclein: from structure and toxicity to therapeutic target
Hilal A. Lashuel et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation
Cintia Roodveldt et al.
PLOS ONE (2013)
Multicellular Self-Assembled Spheroidal Model of the Blood Brain Barrier
Eduard Urich et al.
SCIENTIFIC REPORTS (2013)
Modern methods for delivery of drugs across the blood-brain barrier
Yan Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2012)
Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling
Travis T. Wager et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Richard A. Morgan et al.
HUMAN GENE THERAPY (2012)
Regulatory T cells in the central nervous system
Daniel E. Lowther et al.
IMMUNOLOGICAL REVIEWS (2012)
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?
Natalia N. Nalivaeva et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion
L. Gerard Toussaint et al.
MOLECULAR CANCER (2012)
OPINION Immunotherapy for Alzheimer disease-the challenge of adverse effects
Yu-Hui Liu et al.
NATURE REVIEWS NEUROLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Theranostic Nanomedicine
Twan Lammers et al.
ACCOUNTS OF CHEMICAL RESEARCH (2011)
Current and Emerging Drug Treatment Options for Alzheimerʼs Disease
Nathan Herrmann et al.
DRUGS (2011)
Photodynamic Therapy Boosts Anti-Glioma Immunity in Mice: A Dependence on the Activities of T Cells and Complement C3
Fei Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
James Scott Miners et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Makoto Mitsunaga et al.
NATURE MEDICINE (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Nanoparticle Delivery Systems in Cancer Vaccines
Yogita Krishnamachari et al.
PHARMACEUTICAL RESEARCH (2011)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Cynthia A. Lemere et al.
NATURE REVIEWS NEUROLOGY (2010)
Current Concepts: Nanomedicine.
Betty Y. S. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Marianela Candolfi et al.
CURRENT GENE THERAPY (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Active and passive immunotherapy for Neurodegenerative disorders
David L. Brody et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles
Thomas Schneider et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Synuclein activates microglia in a model of Parkinson's disease
Xiaomin Su et al.
NEUROBIOLOGY OF AGING (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway
Matthew Townsend et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Eric M. Pridgen et al.
NANOMEDICINE (2007)
Central nervous system tumors
Jan C. Buckner et al.
MAYO CLINIC PROCEEDINGS (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
A novel 3D mammalian cell perfusion-culture system in microfluidic channels
Yi-Chin Toh et al.
LAB ON A CHIP (2007)
Internalization of MWCNTs by microglia: Possible application in immunotherapy of brain tumors
Babak Kateb et al.
NEUROIMAGE (2007)
Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 193M mutant
Rieko Setsuie et al.
NEUROCHEMISTRY INTERNATIONAL (2007)
Recent advances in immunotherapy for human glioma
Antoine E. Carpentier et al.
CURRENT OPINION IN ONCOLOGY (2006)
The emerging nanomedicine landscape
Volker Wagner et al.
NATURE BIOTECHNOLOGY (2006)
Immunology and immunotherapy of Alzheimer's disease
HL Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Astrocyte-endothelial interactions at the blood-brain barrier
NJ Abbott et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice
EM Ribé et al.
NEUROBIOLOGY OF DISEASE (2005)
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease
GM Halliday et al.
BRAIN (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease
H Akiyama et al.
NATURE MEDICINE (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
S Oddo et al.
NEURON (2004)
Molecular mechanisms in allergy and clinical immunology
SJ Till et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Targeted therapy for brain tumours
MS Lesniak et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?
G Verdile et al.
PHARMACOLOGICAL RESEARCH (2004)
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
A Schober
CELL AND TISSUE RESEARCH (2004)
Dendritic cell-based immunotherapy of malignant gliomas
P Parajuli et al.
CANCER INVESTIGATION (2004)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias
M Riemenschneider et al.
MOLECULAR PSYCHIATRY (2003)
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
T Wyss-Coray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Innate immunity: The missing link in neuroprotection and neurodegeneration?
MD Nguyen et al.
NATURE REVIEWS NEUROSCIENCE (2002)
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
T Wyss-Coray et al.
NATURE MEDICINE (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
分享论文
